Maximizing the Clinical Benefit of Crizitonib in NSCLC

January 11, 2017
Nicolas Girard, MD

Nicolas Girard, MD, discusses how to maximize the clinical benefit of crizitonib (Xalkori) in non-small cell lung cancer (NSCLC).